Antibody recruiting molecules

Overview

BHV-1100 (previously known as KP1237) is an antibody-recruiting molecule (ARM). ARMs bind to specific targets to facilitate antibody engagement, enhancing immune response against multiple myeloma.

Therapeutics

• Antibody recruiting molecules
  BHV-1100
• Antibody therapy
  • ALLO-647
  • Anselamimab
  • AO-176
  • Birtamimab
  • CAEL-101
  • Daratumumab
  • Denosumab
  • Elotuzumab
  • Isatuximab
  • ISB 1342
  • ISB 1442
  • MOR202
  • TAK-079

Research & Development

The development of BHV-1100 and other ARM candidates is crucial for advancing treatment modalities in multiple myeloma. This tailored approach aims to leverage the body's immune system in innovative ways.

References

For additional details on the therapeutic strategies and ongoing clinical studies, please review our full list of all therapeutics.